Genmab — April 2017
-
Our data further show that Dara activates but does not induce apoptosis in CD38(-) NK cells. Thus, we hypothesize that the combination of Dara and CD38(-) CS1-CAR NK cells can show a synergistic effect on tumor eradication and prevention of MM relapse. Our data indeed demonstrated that the combination of CS1 CAR NK cells with CD38(-) NK cells but not with CD38+ NK cells shows a synergistic effect to eradicate MM cells
-
-
Both CS1 and CD38 are tumor-associated antigens expressed on the surface of MM cancer stem-like cells, suggesting that dual targeting of CS1 and CD38 may prevent relapse. Thus, we investigated the combination therapy with Dara and CS1-CAR NK cells for the treatment of relapsed MM.
-
Overall, we have found Dara was effective in 4 of 6 evaluable non-ETP T-ALL samples. In summary, we found dara is a highly effective novel monotherapy for T-ALL in preclinical models. Based on these results, we are developing an early phase trial for children and young adults with relapsed/refractory T-ALL.
-
-
By inducing the expression of CD38, SY-1425 in combination with DARA elicits tumor cell death and NK cell activation. Based on these findings, a phase 2 clinical study with SY-1425 in combination with an anti-CD38 antibody is planned in AML using an RARA biomarker patient selection strategy.
-
-
The combination of SY-1425 and DARA led to a six-fold increase in tumor cell death relative to the single agent controls, and 5-10 fold increases in NK cell activation is observed only in the SY-1425 and DARA combination treatment of RARA-high AML cell lines.
-
Hold da op. Du har haft travlt gentogen. Så hvad har vi nu? Et præklininsk studie, der påpeger synergi mellem dara og CS1-CAR NK celler i MM. Og dara mono i T-ALL. Et fase 1 studie er planlagt. Samt en kombination af SY-1425 og dara i AML. Et fase 2 studie er planlagt.
-
good find again. we discussed the middle one, SY-1425, on the back of a Yahoo article last week, i think Thursday. It must be this study that they will expand to include Dara: https://clinicaltrials.gov/ct2/show/NCT02807558?term=NCT02807558&rank=1
-
Alcyone er opdateret 7/4. Antallet af lokationer er - siden januar - udvidet fra 179 til 209. Ud af de 209 lokationer er 29 "completed". Ud af 12 US-lokationer er 7 "completed". https://www.clinicaltrials.gov/ct2/show/study/NCT02195479?term=daratumumab+and+velcade&rank=1&show_locs=Y#locn
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind